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Male to female ratio was 17:29, mean age was 52.7 years (ranged from 
31 to 74 years). Relapse free time varied from 6 months to 5 years. All 
patients had abnormal radiographic ﬁnding. Radiography was done on 
routine control examination in 60% of patients, who had no symptoms. 
The most common primary malignancy was laryngeal carcinoma 
(22pts-47.8%), breast carcinoma (6pts-13%), adenocarcinoma of the 
colon (5pts-10.8%), thyroid gland carcinoma (5pts-10.8%) cervical 
carcinoma of the uterus (3pts-6.52%) and other, less common tumors 
(stomach, esophagus, prostate, tongue). Bronchoscopic ﬁnding revealed 
that endoluminal metastases were more common in right lung (in 31 
pts-67.4%). Most of the metastases were seen in upper lobe bronchi 
(52%). Biopsy was performed and pathohistological veriﬁcation was 
obtained in all patients. In more then 1/2 of the patients histologic type 
was squamocellular carcinoma.
We can conclude that ﬁberoptic bronchoscopy with biopsy is simple, 
cheap technique in diagnosis of endobronchial metastases. Histological 
veriﬁcation is 100% in centrally localized lesions.
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I would like to present the mediastinal adenosuamous cell carcinoma 
involved the left subclavian artery, left brachiocepharic vein, left recur-
rent nerve and left phrenic nerve. 
A 48-year-old male visited our institute with abnormal ﬁndings of 
left upper mediastinal on chest X ray. The left subclavian artery was 
involved with the tumor of 5.0 X 4.5 cm in diameter on chest CT scan. 
However, there were no left shoulder pain and lower arterial pressure 
of the left upper extremities than the right upper extremities. VATS 
(video-assisted thoracoscopic surgery) was performed for pathologi-
cal diagnosis, and the pathological diagnosis was adenosquamous cell 
carcinoma. PET (positron emission tomography) scan revealed the 
just uptake of the tumor site. So, we performed the mediastinal tumor 
resection and the combined resection of the left subclavian artery, the 
left brachiocepharic vein, left recurrent nerve and left phrenic nerve. 
The left subclavian artery reconstructed with Gelwaeve 8mm, and the 
left brachiocepharic vein reconstructed with ringed e-PTFE 10mm. The 
postoperative course was smooth and not eventful, he was discharge on 
the 10 days after operation.
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experience (1996-2006)
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The aim of the study was to analyse clinical features and 1-yr survival 
rate of bronchial carcinoid patients diagnosed at the Institute of Lung 
Diseases and TB in Belgrade 1996-2006. 
The group consists of 58 pts (30 females and 28 males), the average 
age of 48 ys (17 - 75). 57 of them underwent operation: lobectomy in 
34pts (58.6.%), pneumonectomy in 11pts(19%), atypical resection in 
9pts (15.5%), bilobectomy in 3pts (5.2%). Hystologic ﬁnding of typical 
carcinoid tumor was in 39pts (67.2%), while atypical in 19pts (32.8%). 
Central tumor type was noted in 30pts(51.7%) and peripheral in 28pts 
(48.3%). CT scan showed that majority of peripheral tumors were 
3-3.5cmX4-4.5cm in diameter, with the exception of 1 case with the 
tumor size 8x7cm and 2 of size 6x5cm.
The most frequent symptoms were cough -30pts (51.7%), chest pain-
25pts (43.1%), dyspnoea -20pts (34.5%), haemoptysis-19pts (32.7%), 
fever-18pts(31.0%), weight loss-13pts (22.4%) and fatigue-12pts 
(20.7%). Majority of pts had disease symptoms lasting either 1 year 
and longer-25pts (43.1%) or less than 3 months -16pts (27.6%).
Five pts (8.6%) had associated neuroendocrine disorder or tumor either 
in the previous history or at the same time of bronchial carcinoid tumor 
diagnosis. Only one pt with Kushing Sy persisting after operation of 
gonadotropic adenoma of pituitary gland, has shown to have hormonal 
activity of the peripheral bronchial carcinoid tumor since this Sy re-
solved after lung operation.
The 1-year follow-up analysis shows 1-year survival rate of 86.2% 
(50pts): 8pts died within the ﬁrst year after diagnosis or operation. One 
pt died 6th day after operation due to fatal pulmonary embolism, and 
other 7 pts died due to metastatic disease relapse 
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In vitro activity of picropodophyllin in lung cancer cell lines and 
association to the insulin-like Growth Factor-1 receptor
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Background: Insulin-like Growth Factor-1 (IGF-1) and its receptor 
(IGF-1R) are important for transformation and growth of malignant 
cells and for the prevention of apoptosis. IGF-1R is often over-ex-
pressed in malignant tumors and several oncogenes depend on intact 
IGF-1R to achieve their transforming activity. 
Recently, members of the cyclolignan family were identiﬁed as poten-
tial inhibitors of the IGF-1 receptor tyrosine kinase. Picropodophyllin 
(PPP), in particular, shows promise since it demonstrates selectivity for 
IGF-1R without inhibiting activity of the insulin receptor or other more 
distantly related receptors. There is, however, on ongoing debate if 
inhibition of microtubule assembly contributes to the cytotoxic effects 
of PPP as this is the major mechanism of action for its epimer podo-
phyllotoxin, PPT. Tumor cells of lung cancer also express IGF-1-re-
ceptors, but their role in the malignant phenotype is still not clear. The 
aim of this study was to investigate the role of IGF-1R in lung cancer 
and to evaluate its potential as a therapeutic target through use of PPP, 
a speciﬁc tyrosine kinase inhibitor of IGF-1R. We also investigated 
the relation between IGF-1 receptor status in cells and sensitivity to 
conventional and experimental chemotherapeutic agents, including PPT 
and other microtubule inhibiting agents.
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Methods: Expression levels of IGF-1R was evaluated by immuno-
precipitation using antibodies directed against IGF-1R, followed by 
SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) and Western 
blotting. 9 different cell lines, including both non-small cell and small 
cell lung cancer, were used in the analyses. Using the panel of IGF-1R 
expressing cell lines, we studied PPP-induced cell death by means of 
Fluorometric Microculture Cytotoxicity Assay (FMCA). We also com-
bined PPP treatment with a panel of various cytotoxic drugs in order to 
study potentially additive or synergistic effects. Gene expression proﬁl-
ing using the microarray technique on an Affymetrix platform was used 
to characterize the cell lines. Quantitative real-time RT-PCR was used 
to validate gene expression levels.
Results: The sensitivity to PPP differed between the various cell lines, 
yielding IC50-values ranging from below 1 to almost 100 μM. Within 
the tested concentration range PPP-effects were nicely dose-dependent, 
and the shapes of the concentration-response curves differed from those 
of PPT which were much shallower. However both drugs shared cell 
lines in which the highest and lowest activity was seen, and correlation 
analysis of endpoints yielded moderate correlation coefﬁcients. In ad-
dition, a panel of various cytotoxic drugs was tested in its effect on the 
lung cancer cells and a wide variation in sensitivity was noted between 
the cell lines. The gene expression proﬁles of the cells were examined 
using microarray technique and by statistical analyses, the proﬁles were 
evaluated for correlation with sensitivity to PPP. Further data on these 
analyses will be presented at the meeting. We also plan to study the 
effect of PPP on IGF-R signaling in the aformentioned cell lines from 
lung cancer and its importance to tumor biology, elucidating which 
signal proteins and pathways are affected by the treatment. 
Conclusions: IGF-1R constitutes a potential therapeutic target in lung 
cancer and since regulation of the IGF-1R signal pathway is disrupted 
in a variety of tumors, inhibitors may be useful in various diagnoses. 
The cyclolignan picropodophyllin (PPP) signiﬁcantly decreased cell 
viability in a concentration dependent manner in all lung cancer cell 
lines. PPP has been described as a speciﬁc inhibitor of IGF-1R, but 
in these experiments effects appear affected also by other, additional, 
mechanisms. 
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Background: Previous characterization of the novel melphalan 
containing pro-drugs J1 and J3 have revealed an increased cytotoxic-
ity in human tumour cells of various origins compared to the parental 
substance melphalan (Gullbo et al., 2003). J1 is now in a Phase I trial. 
In order to get increased knowledge about the cellular signalling trig-
gered by the melphalan-containing pro-drugs and trying to understand 
possible synergies with conventional chemotherapies, we have here 
compared the effects of J1, J3 and melphalan in NSCLC cell lines. 
Methods: NSCLC cells have been treated with either J1, J3 or melpha-
lan alone or in combination with standard chemotherapy. Cell viability 
upon treatments have been assessed using FMCA or MTT methods. 
Apoptotic signalling parameters (caspase-3 activation, mitochondrial 
depolarization, Bcl-2 family protein activation, Mitogen activated 
protein kinase (MAPK) activation) have been examined at various time 
points post treatment using a combination of ﬂow cytometry, western 
blotting and immunoﬂurescence microscopy analysis. 
Results and Conclusion: We report here that the melphalan pro-drug 
J1 causes a more rapid induction of apoptosis compared to melphalan 
in NSCLC cells. Moreover, our data show that J1-induced apoptotic 
signalling involves activation of Bak and Bax, depolarisation of mito-
chondria and activation of caspase-3. We report here that J1 causes an 
increased and more sustained activation of the MAPK JNK compared 
to melphalan. A role for JNK in J1-mediated cytotoxicity is shown by 
using pharmacological inhibitors. The importance of various cellular 
compartments for J1-mediated apoptotic signalling and the possible 
synergy with standard chemotherapy will also be discussed.
Reference:
 Gullbo J, Tullberg M, Vabeno J, Ehrsson H, Lewensohn R, Nygren P, Larsson R, Luth-
man K. (2003) Structure-activity relationship for alkylating dipeptide nitrogen mustard 
derivatives.Oncol Res. 14(3):113-32.
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Comparison of vinorelbine plus oxaliplatin or cisplatin for 
treatment of advanced lung adenocarcinoma
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Objective: To observe and compare the effect and side reaction of two 
kinds of combined chemotherapy in treating patients with advanced 
lung adenocarcinoma. One is Vinorelbine plus Oxaliplatin (NO) AND 
THE OTHER IS Vinorelbine plus Cisplatin (NP). 
Methods: 120 patients with advanced lung adenocarcinoma were 
divided into two groups. One group was treated with NO and the other 
was treated with NP,. Patients in two groups were well-matched in 
basic characteristics. All of them were treated by the two regimens 
responsively for 2 or 3 cycles. 
Results: The reponse rate was 43.3% in group NO and 45.0% in group 
NP. The median survival duration, one-year survival rate and three-year 
survival rate in NO group were eleven months, 38.3% and 8.3%; and 
in group NP they were ten months, 38.3% and 10.0%. There was no 
statistics difference in the curative effect of the two groups(P<0.05). 
Bone marrow inhibition was dose-limited toxicity of the two groups. 
The rates of III degree-IV degree neutropenia in group NO and NP 
were 22.2% and 21.6% (P<0.05). The rate of alimentary canal reaction 
in group NP was higher than the rate in group NO (P<0.05).The rate 
of renal disfunction in group NP was higher than the rate in group NO 
(P<0.05). The rate of neurotoxicity in group NO is higher the rate in 
group NP (P<0.05),but all patients, neurotoxicity can be renewed after 
chemotherapy. The rate of other unwanted reactions in two groups is 
similar. All side reactions can be endured. 
Conclusion: Both NO and NP are effective and safe in treating patients 
with advanced lung adenocarcinoma. The two regimens have the 
close curative effect. And the side reactions are similar. However, NO 
regimen has slighter toxicity in gastrointestin and renal function, so 
patients can endure better.
